Live Breaking News & Updates on அகாடியா மருந்துகள்|Page 6

Stay updated with breaking news from அகாடியா மருந்துகள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

ROSEN, A LEADING LAW FIRM, Encourages Acadia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important June 18 Deadline in Securities Class Action – ACAD


Home / Top News / ROSEN, A LEADING LAW FIRM, Encourages Acadia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important June 18 Deadline in Securities Class Action – ACAD
ROSEN, A LEADING LAW FIRM, Encourages Acadia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important June 18 Deadline in Securities Class Action – ACAD
NEW YORK, May 30, 2021 (GLOBE NEWSWIRE)
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) between June 15, 2020 and April 4, 2021, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court ....

New York , United States , Laurence Rosen , Phillip Kim , Chinese Company , Drug Administration , Securities Class Action Services , Rosen Law Firm , Acadia Pharmaceuticals Inc , Acadia Pharmaceuticals , Class Period , Law Firm , Class Action Services , New Drug Application , Class Has Been , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , லாரன்ஸ் ரோஸன் , பிலிப் கிம் , சீன நிறுவனம் , பத்திரங்கள் வர்க்கம் நடவடிக்கை சேவைகள் , ரோஸன் சட்டம் நிறுவனம் , அகாடியா மருந்துகள் இன்க் , அகாடியா மருந்துகள் , வர்க்கம் காலம் , சட்டம் நிறுவனம் ,

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Acadia Pharmaceuticals Inc. (ACAD) Investors


Share this article
Share this article
LOS ANGELES, May 28, 2021 /PRNewswire/ The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Acadia Pharmaceuticals Inc. ( Acadia or the Company ) (NASDAQ: ACAD) securities between
June 15, 2020 and April 4, 2021, inclusive (the Class Period ). Acadia investors have until
June 18, 2021 to file a lead plaintiff motion.
If you are a shareholder who suffered a loss, click here to participate.
Acadia is a biopharmaceutical company that develops a drug called pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia, as well as an adjunctive treatment for major depressive disorder. In June 2020, Acadia submitted a supplemental New Drug Application ( sNDA ) with the U.S. Food and Drug Administration ( FDA ) to expand pimavanserin s label to include treatment for dement ....

United States , Los Angeles , Frankr Cruz , Drug Administration , Acadia Pharmaceuticals Inc , Law Offices , Acadia Pharmaceuticals , New Drug Application , Complete Response Letter , Class Period , Attorney Advertising , The Law Offices Of Frankr Cruz , Los Angeles , ஒன்றுபட்டது மாநிலங்களில் , லாஸ் ஏஞ்சல்ஸ் , அகாடியா மருந்துகள் இன்க் , சட்டம் அலுவலகங்கள் , அகாடியா மருந்துகள் , புதியது மருந்து விண்ணப்பம் , முழுமை பதில் கடிதம் , வர்க்கம் காலம் ,